Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe - Seite 2

Sandoz produces enough penicillin products at Kundl to potentially meet all current Europe-wide demand. Kundl is the Sandoz competence center for antibiotic FDFs and the focal point of its European antibiotics manufacturing network. Sandoz is the #1 global supplier of generic antibiotics.

For more information, please visit our digital press kit: https://www.sandoz.com/future-antibiotics-manufacturing-europe

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as  “plans,” “planned,” “intends, “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” or similar terms, or by express or implied discussions regarding plans for a joint investment, together with the Austrian federal government, to strengthen the long-term competitiveness of Sandoz integrated antibiotic manufacturing operations at Kundl, or regarding potential future revenues from the products described in this press release. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the planned joint investment with the Austrian federal government to strengthen the long-term competitiveness of Sandoz integrated antibiotic manufacturing operations at Kundl will close in the anticipated time frame, or at all. Neither can there be any guarantee that, such planned joint investment will achieve any or all of its intended goals in any particular time frame, or at all. Nor can there be any guarantee that the products described in this press release will be commercially successful in the future. In particular, our expectations regarding  the planned joint investment with the Austrian federal government and such products could be affected by, among other things, the failure by either party to obtain formal approvals for the planned joint investment; the failure to develop new process technology to produce API for penicillin products at Kundl in the expected time frame, or at all; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including  price competition with Sandoz penicillin products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.